Encore Dermatology Inc. launched its new topical product, Impoyz Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.

“Psoriasis patients are some of the most challenging to treat because of the chronic nature of the disease and the effect it has on their quality of life,” said Mark Lebwohl, MD, Professor and Chairman of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai. “Impoyz Cream gives dermatology providers the opportunity to treat moderate to severe psoriasis patients with an active ingredient they know well in a new, modern formulation.”

Impoyz Cream contains clobetasol propionate 0.025% in a modern vehicle. This specially formulated product is effective in reducing the signs and symptoms of plaque psoriasis while offering a favorable tolerability and safety profile. The active ingredient in Impoyz Cream, clobetasol propionate, is one of the most widely used corticosteroids for the treatment of psoriasis.

For more than 30 years, clobetasol propionate has been available in only one strength. “Now we are especially excited to launch Impoyz Cream, as it offers dermatology providers with their first new strength as an alternative to traditional clobetasol—allowing providers to treat their patients with a lower concentration,” said Bob Moccia, president and CEO of Encore Dermatology.

Impoyz Cream is available in the US by prescription only in a 60g tube.